COMPANY RESEARCH PROFILE · UPDATED 2026-09-29

Revolution Medicines Inc

Precision-oncology company developing RAS-pathway medicines; its portfolio includes the RAS(ON) multi-selective inhibitor daraxonrasib and mutant-selective RAS inhibitors.

TICKERRVMD

HEADQUARTERSRedwood City, United States

STAGEApproved

ACTIVE TRIALS15

Therapeutic areas

Oncology

Selected products and programs

daraxonrasibelironrasibzoldonrasib

Linked curated drug profiles

No curated drug entity is linked in the current pilot.

Selected active clinical trials

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Phase 3 · Recruiting · NSCLC (Non-small Cell Lung Cancer)

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 3 · Recruiting · Pancreatic Cancer

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Phase 3 · Recruiting · Pancreatic Cancer

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

Phase 3 · Recruiting · Pancreatic Cancer

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 3 · Recruiting · Pancreatic Cancer

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Phase 3 · Recruiting · NSCLC

Selected patent records

No linked FDA Orange Book patent record was found for the selected products.

Primary and company sources

Company and pipeline information can change. Verify material decisions against the linked primary sources.

Evidence & limits

Source: Open the source record

Record identifier: /companies/revolution-medicines-inc/
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.

Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.

Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.

What this record means · Report an issue with this record